Download PDF
Thromb Haemost 1993; 69(04): 366-369
DOI: 10.1055/s-0038-1651613
Original Article
Coagulation
Schattauer GmbH Stuttgart

Distribution of Tissue Factor Pathway Inhibitor in Normal and Malignant Human Tissues

Robert W Werling
1   The VA Medical Center, White River Junction, Vermont, USA
2   The Department of Medicine, Hanover, New Hampshire
,
Leo R Zacharski
1   The VA Medical Center, White River Junction, Vermont, USA
2   The Department of Medicine, Hanover, New Hampshire
,
Walter Kisiel
4   The Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico
,
S Paul Bajaj
5   The Department of Biochemistry and Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri, USA
,
Vincent A Memoli
3   The Department of Pathology, Dartmouth Medical School, Hanover, New Hampshire
,
Sandra M Rousseau
1   The VA Medical Center, White River Junction, Vermont, USA
› Author Affiliations
Further Information

Publication History

Received 19 May 1992

Accepted after revision 17 December 1992

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Specific antibodies to tissue factor pathway inhibitor (TFPI) were used in immunohistochemical procedures to determine the distribution of TFPI in normal and neoplastic human tissues. TFPI was restricted to megakaryocytes and the endothelium of the microvasculature in normal and abnormal tissues, but was not found in the endothelium of larger vessels or in hepatocytes. TFPI was also detected in macrophages in the villi of term placenta. Tumor-associated macrophages in several types of malignancy that we have shown previously to express a complete tissue factor-initiated pathway of coagulation and thrombin generation also manifested TFPI. By contrast, malignant cells in small cell carcinoma of the lung, renal cell carcinoma, and malignant melanoma that we have shown previously to express coagulation factors together with tumor cell-associated fibrin formation failed to stain for TFPI. We postulate that TFPI may be lacking from the latter malignancies because of the absence of the appropriately configured tissue factor – factor VII a – factor Xa complex required for TFPI binding.

 

  • References

  • 1 Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemostas 1991; 66: 6-15
    PubMedGoogle Scholar
  • 2 Broze GJ, Girard TJ, Novotny WF. The lipoprotein-associated coagulation inhibitor. In: Progress in Hemostasis and Thrombosis, 10. Coller BS. (ed). Philadelphia, PA: W. B. Saunders; 1990: 243-268
    Google Scholar
  • 3 Sandset PM. Abildgaard UExtrinsic pathway inhibitor - the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-239
    PubMedGoogle Scholar
  • 4 Zacharski LR, Memoli VA, Costantini V, Wojtukiewicz MZ, Ornstein DL. Clotting factors in tumor tissue: Implications for cancer therapy. Blood Coagul Fibrinolys 1990; 1: 71-78
    PubMedGoogle Scholar
  • 5 Zacharski LR, Memoli VA, Rousseau SM, Kisiel W. Coagulation-cancer interaction in situ in a small cell carcinoma of the lung. Cancer 1987; 60: 2675-2681
    CrossrefPubMedGoogle Scholar
  • 6 Zacharski LR, Memoli VA, Rousseau SM. Thrombin-specific sites of fibrinogen in small cell carcinoma of the lung. Cancer 1988; 62: 299-302
    CrossrefPubMedGoogle Scholar
  • 7 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990; 65: 481-485
    CrossrefPubMedGoogle Scholar
  • 8 Zacharski LR, Dunwiddie C, Nutt EM, Hunt J, Memoli VA. Cellular localization of activated factor X by a Xa-specific probe. Thromb Haemostas 1991; 65: 545-548
    PubMedGoogle Scholar
  • 9 Zacharski LR, Memoli VA, Rousseau SM. Cancer-coagulation interaction in situ in renal cell carcinoma. Blood 1986; 68: 394-399
    PubMedGoogle Scholar
  • 10 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990; 10: 579-582
    PubMedGoogle Scholar
  • 11 Wojtukiewicz MZ, Zaharski LR, Memoli V, Kisiel W, Kudryk BJ, Rousseau SA, Stump DC. Malignant melanoma: Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93: 516-521
    CrossrefPubMedGoogle Scholar
  • 12 Ornstein D, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Hunt J, Rousseau SM, Stumo DC. Coexistant macrophage procoagulant and tumor cell plasminogen activator in adenocarcinoma and squamous cell carcinoma of the lung. Cancer 1991; 68: 1061-1067
    CrossrefPubMedGoogle Scholar
  • 13 Costantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Hunt J, Rousseau SM, Stump DC. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 1991; 51: 349-353
    PubMedGoogle Scholar
  • 14 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SA, Stump DC. Indirect activation of blood coagulation in colcon cancer. Thromb Haemostas 1990; 62: 1062-1066
    PubMedGoogle Scholar
  • 15 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Moritz TE, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 1991; 67: 1377-1383
    CrossrefPubMedGoogle Scholar
  • 16 Costantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Fibrinogen deposition and macrophage-associated fibrin formation in malignant and non-malignant lymphoid tissue. J Lab Clin Med 1992; 119: 124-131
    PubMedGoogle Scholar
  • 17 Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Moeller KB, Meidahl-Pedersen J, Beck TC, Norris K, Hedner U, Kisiel W. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reaction. J Biol Chem 1990; 265: 16786-16793
    PubMedGoogle Scholar
  • 18 Sakai T, Lund-Hansen T, Paborsky L, Pedersen AH, Kisiel W. Binding of human factors VII and Vila to a human bladder carcinoma cell line. J Biol Chem 1989; 264: 9980-9988
    PubMedGoogle Scholar
  • 19 Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci 1990; 87: 8869-8873
    CrossrefPubMedGoogle Scholar
  • 20 Spindler KS, Rosser DSE, Berk AJ. Analysis of adenovirus transforming proteins from early regions 1 A and 1 B with antisera to inducible fusion antigens produced in E.coli. . J Virol 1984; 49: 132-141
    PubMedGoogle Scholar
  • 21 Novotny WF, Girard TJ, Miletich JP, Broze GJ. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988; 72: 2020-2025
    PubMedGoogle Scholar
  • 22 Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood. 1992 in press
    PubMedGoogle Scholar
  • 23 Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-1878
    CrossrefPubMedGoogle Scholar
  • 24 van der Logt CP, Reitsma PH, Bertina RM. LACI transcripts in human monocytes is not stimulated by agonists that induce tissue factor expression. Thromb Haemostas 1991; 65: 702
    PubMedGoogle Scholar
  • 25 Rana SV, Reimers HJ, Pathikonda MS, Bajaj SP. Expression of tissue factor and factor VIIa/tissue factor inhibitor activity in endotoxin or phorbol ester stimulated U937 monocyte-like cells. Blood 1988; 71: 259-262
    PubMedGoogle Scholar
  • 26 Amery A, Hyers TM, Tricomi S, Kuppuswamy MN, Bajaj SP. Transcriptional expression of tissue factor pathway inhibitor in alveolar macrophages of patients with adult respiratory distress syndrome. Blood (Suppl. 01) 1991; 78: 106a
    PubMedGoogle Scholar
  • 27 Edwards RL, Rickles FR. Macrophage procoagulants. In: Progress in Hemostasis and Thrombosis. Spaet TH. Philadelphia PA: W. B. Saunders; 1984: 183-209
    Google Scholar
  • 28 Gemmell CH, Broze GJ, Turitto VT, Nemerson Y. Utilization of a continuous flow reactor to study the lipoprotein-associated coagulation inhibitor (LACI) that inhibits tissue factor. Blood 1990; 76: 2266-2271
    PubMedGoogle Scholar
  • 29 Schoen P, Blezer R, Nordfang O, Reutelingsberger L. Activation of factor X by endothelial cell tissue factor in an open, laminar flow reactor, and its regulation by extrinsic pathway inhibitor. Thromb Haemostas 1991; 65: 768
    PubMedGoogle Scholar
  • 30 Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Schwartzman reaction. Blood 1991; 78: 1496-1502
    PubMedGoogle Scholar
  • 31 Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 708-712
    CrossrefPubMedGoogle Scholar
  • 32 Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze GJ, Warren TG, Wun T-C. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravas-cular coagulation in the rabbit. Blood 1990; 76: 1538-1545
    PubMedGoogle Scholar
  • 33 Haskel EJ, Torr SR, Day KC, Palmier MO, Wun T-C, Sobel BE, Abendschein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lypoprotein-associated coagulation inhibitor. Circulation 1991; 84: 821-827
    CrossrefPubMedGoogle Scholar
  • 34 Carson SD, Haire WD, Broze GJ, Novotny WF, Pirrucello SJ, Duggan MJ. Lipoprotein associated coagulation inhibitor, factor VII, antithrombin III, and monocyte tissue factor following surgery. Thromb Haemostas 1991; 66: 534-539
    PubMedGoogle Scholar
  • 35 Lindahl AK, Sandset P, Harbitz T, Anderson T, Abildgaard U. High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand 1989; 155: 389-393
    PubMedGoogle Scholar
  • 36 Lindahl AK, Hammer AKG, Boffa MC. Thrombomodulin and extrinsic pathway inhibitor in plasma are increased in pancreatic carcinoma, but by different mechanisms. Thromb Haemostas 1991; 65: 950
    PubMedGoogle Scholar
  • 37 Lindahl AK, Odegaard OR, Sandset PM, Abildgaard U. Increased extrinsic pathway inhibitor levels in pancreatic cancer is related to progress of malignant disease, and also to biliary stasis. Thromb Haemostas 1991; 65: 951
    PubMedGoogle Scholar
  • 38 Novotny WF, Palmier M, Wun TC, Broze GJ, Miletech JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394-400
    PubMedGoogle Scholar
  • 39 Abildgaard U, Lindahl AK, Larsen ML, Staalesen R, Sandset PM. Heparin anticoagulates blood through anti-thrombin, through extrinsic pathway inhibitor (EPI), and through an unidentified mechanism. Thromb Haemostas 1991; 65: 951
    PubMedGoogle Scholar
  • 40 Hinz U, Grulich-Henn J, Preissner KT, Muller-Berghaus G. Mechanism of extrinsic pathway inhibitor stimulation by heparin in umbilical vein endothelial cells. Thromb Haemostas 1991; 65: 952
    PubMedGoogle Scholar
  • 41 Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155-168
    CrossrefPubMedGoogle Scholar
  • 42 Pedersen AH, Komiyama Y, Tracy PB, Nordfang O, Kisiel W. The effect of factor Va on the inhibition of factor Xa by recombinant human extrinsic pathway inhibitor. Thromb Haemostas 1991; 65: 951
    PubMedGoogle Scholar